STOCK TITAN

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
buyback
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) has announced a $50 million share repurchase agreement with Walgreens Boots Alliance Holdings LLC, in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933. The company intends to repurchase shares at the price per share equal to the price in the Rule 144 sale, under its share repurchase program. The repurchased shares will be held in treasury.
Positive
  • None.
Negative
  • None.

The decision by Cencora, Inc. to repurchase shares concurrent with Walgreens Boots Alliance's sale is a strategic financial move that can have multiple implications for the company's capital structure and shareholder value. By repurchasing shares at the market price determined by the Rule 144 sale, Cencora is potentially signaling to the market that it believes its stock is undervalued. This action could be perceived as a positive signal by investors, leading to a potential increase in the stock's demand and price.

Moreover, the repurchase will reduce the number of outstanding shares, which may lead to an increase in earnings per share (EPS), a key metric used by investors to gauge a company's profitability. This could make the stock more attractive to value investors. However, it's important to consider the source of funds for this repurchase. If the buyback is financed through debt, it could increase the company's leverage, potentially impacting its financial stability. Analyzing the company's balance sheet and cash flow statements would provide further insights into the sustainability of such share repurchase programs.

The share repurchase by Cencora also has implications for the broader market perception of the company's industry and sector performance. It is essential to analyze the industry trends to understand why Cencora may have chosen to invest in its own shares rather than other growth opportunities. This could reflect a lack of viable investment opportunities within the industry or a strategic shift towards shareholder return maximization.

Additionally, the timing and scale of the repurchase could influence market dynamics. If the repurchase is executed during a period of low liquidity, it could disproportionately impact the stock price. Understanding the historical performance of Cencora's stock during similar transactions and the current market conditions will provide a comprehensive view of the potential market impact of this repurchase.

It is notable that the share repurchase is being conducted under Rule 144, which governs the sale of restricted and control securities. This rule allows for the public resale of unregistered shares under certain conditions, which can include a holding period and volume limitations, among others. The adherence to Rule 144 ensures regulatory compliance and minimizes legal risks associated with the transaction.

The share repurchase program must be carefully structured to comply with securities laws and regulations to prevent potential issues such as market manipulation. It is also important for shareholders to understand the legal framework of such transactions, as it can affect the timing and execution of the repurchase, as well as any subsequent resale of the treasury shares. The company's disclosure of the repurchase details is crucial for maintaining transparency and trust with its investors.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.

Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora’s share repurchase program and the repurchased shares will be held in treasury.

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at investor.cencora.com

Bennett S. Murphy

Senior Vice President, Head of Investor Relations & Treasury

610-727-3693

Bennett.Murphy@cencora.com

Source: Cencora

FAQ

What is the ticker symbol for Cencora, Inc.?

The ticker symbol for Cencora, Inc. is COR.

What is the amount of the share repurchase agreement with Walgreens Boots Alliance Holdings LLC?

Cencora, Inc. has agreed to repurchase shares from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million.

Under which rule is the share repurchase being made?

The share repurchase will be made under Rule 144 under the Securities Act of 1933.

Where will the repurchased shares be held?

The repurchased shares will be held in treasury under Cencora's share repurchase program.

Cencora, Inc.

NYSE:COR

COR Rankings

COR Latest News

COR Stock Data

44.70B
172.33M
13.5%
87.47%
4.07%
Drugs and Druggists' Sundries Merchant Wholesalers
Wholesale Trade
Link
United States of America
CONSHOHOCKEN

About COR

amerisourcebergen is driving innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain and enhance patient care. as the leader in global sourcing and distribution, we source and distribute brand, generic, specialty, otc pharmaceuticals and other healthcare products. we increase the effectiveness and efficiency of your supply chain by ensuring products are delivered securely, consistently and cost-effectively, improving product access for pharmacies, providers and patients. our pharmacy solutions result in greater operational efficiency, cost control, growth opportunities and patient safety. our provider solutions drive operational efficiency, financial performance and improve quality of care. our manufacturer solutions maximize success at every stage of the product lifecycle. amerisourcebergen. where knowledge, reach and partnership shape healthcare delivery.